Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.60 |
| ▸ | THRA | P10827 | 4/20 | 0.60 |
| ▸ | RHEB | Q15382 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274795 | 0.87 | THRB (0.45) | THRBTHRAPTGS1PTGS2LGALS8 | |
| SCHEMBL6275903 | 0.84 | THRB (0.70) | THRBTHRARHEBPTGS1PTGS2 | |
| SCHEMBL1640505 | 0.83 | THRB (0.47) | THRBTHRARHEBPTGS1PTGS2 | |
| SCHEMBL6273892 | 0.83 | THRB (0.67) | THRBTHRARHEBGRIN1 | |
| SCHEMBL6269592 | 0.81 | THRB (0.45) | THRBTHRAPTGS1PTGS2MEN1 | |
| SCHEMBL1642215 | 0.80 | THRA (0.71) | THRBTHRARHEB | |
| SCHEMBL6274993 | 0.79 | THRB (0.59) | THRBTHRARHEBGRIN1 | |
| SCHEMBL1640579 | 0.79 | THRB (0.59) | THRBTHRARHEBLGALS8GRIN1 | |
| SCHEMBL6269595 | 0.78 | THRB (0.42) | THRBTHRAPTGS1PTGS2POLB | |
| SCHEMBL1642156 | 0.78 | THRB (0.58) | THRBTHRARHEBGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098303-A1 | Method of promoting nail growth using thyromimetic compounds | DOHERTY NIALL S | 2011-04-28 | — | — | US | claimed |
| EP-1297833-B1 | Indole carboxylic acids as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004047827-A1 | METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-6723744-B2 | FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA | PFIZER, INC. | 2004-04-20 | — | — | US | claimed |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | ASPNES GARY E (US) | 2003-04-24 | — | — | US | claimed |
| EP-1297833-A1 | Indole carboxylic acids as thyroid receptor ligands | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| US-20110098303-A1 | Method of promoting nail growth using thyromimetic compounds | DOHERTY NIALL S | 2011-04-28 | — | — | US | disclosed |
| EP-1297833-B1 | Indole carboxylic acids as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004047827-A1 | METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-6723744-B2 | FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA | PFIZER, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | ASPNES GARY E (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1297833-A1 | Indole carboxylic acids as thyroid receptor ligands | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098303-A1 | Method of promoting nail growth using thyromimetic compounds | TPO, POLR1C, TYR | THRB 29/4885THRA 21/4885RHEB 2871/4885 |
| US-20030078289-A1 | Indole carboxylic acids as thyroid receptor ligands | THRA, MC1R, THRB | THRB 3/4885THRA 1/4885RHEB 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.